The use of OKT3 rescue therapy after orthotopic liver transplantation - The University of Nebraska Medical Center Experience

R. P. Wood, Byers Wendell Shaw Jr, L. Williams

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

At the University of Nebraska Medical Center (UNMC), a protocol was instituted in July 1985 for the use of OKT3 on a compassionate basis for patients who failed treatment of acute rejection with both steroids and Atgam. (ATG). This paper summarizes the results of our conventional immunosuppression with cyclosporine (Cs) and steroids, conventional therapy for acute rejection including steroids and ATG, and compassionate use of OKT3. We conclude that reserving OKT3 for use as the final-line therapy, after SR and Atgam have failed, yields results inferior to those obtained when OKT3 is used to treat steroid-resistant rejections. Our experience has shown, however, that most rejection episodes after OLT are readily reversed by using steroid therapy as outlined. From the data presented, OKT3 is at least as effective as Atgam in treating steroid-resistant rejections. In addition, OKT3 has the added advantage of being readily available and does not appear to be associated with a higher incidence of complications than does Atgam therapy.

Original languageEnglish (US)
Pages (from-to)254-259
Number of pages6
JournalTransplantation Proceedings
Volume20
Issue number1 SUPPL. 1
StatePublished - Jan 1 1988

Fingerprint

Muromonab-CD3
Liver Transplantation
Steroids
Therapeutics
Compassionate Use Trials
Immunosuppression
Cyclosporine
Incidence

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

The use of OKT3 rescue therapy after orthotopic liver transplantation - The University of Nebraska Medical Center Experience. / Wood, R. P.; Shaw Jr, Byers Wendell; Williams, L.

In: Transplantation Proceedings, Vol. 20, No. 1 SUPPL. 1, 01.01.1988, p. 254-259.

Research output: Contribution to journalArticle

Wood, R. P. ; Shaw Jr, Byers Wendell ; Williams, L. / The use of OKT3 rescue therapy after orthotopic liver transplantation - The University of Nebraska Medical Center Experience. In: Transplantation Proceedings. 1988 ; Vol. 20, No. 1 SUPPL. 1. pp. 254-259.
@article{8aff59083be947f1b0217a6794dbe974,
title = "The use of OKT3 rescue therapy after orthotopic liver transplantation - The University of Nebraska Medical Center Experience",
abstract = "At the University of Nebraska Medical Center (UNMC), a protocol was instituted in July 1985 for the use of OKT3 on a compassionate basis for patients who failed treatment of acute rejection with both steroids and Atgam. (ATG). This paper summarizes the results of our conventional immunosuppression with cyclosporine (Cs) and steroids, conventional therapy for acute rejection including steroids and ATG, and compassionate use of OKT3. We conclude that reserving OKT3 for use as the final-line therapy, after SR and Atgam have failed, yields results inferior to those obtained when OKT3 is used to treat steroid-resistant rejections. Our experience has shown, however, that most rejection episodes after OLT are readily reversed by using steroid therapy as outlined. From the data presented, OKT3 is at least as effective as Atgam in treating steroid-resistant rejections. In addition, OKT3 has the added advantage of being readily available and does not appear to be associated with a higher incidence of complications than does Atgam therapy.",
author = "Wood, {R. P.} and {Shaw Jr}, {Byers Wendell} and L. Williams",
year = "1988",
month = "1",
day = "1",
language = "English (US)",
volume = "20",
pages = "254--259",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "1 SUPPL. 1",

}

TY - JOUR

T1 - The use of OKT3 rescue therapy after orthotopic liver transplantation - The University of Nebraska Medical Center Experience

AU - Wood, R. P.

AU - Shaw Jr, Byers Wendell

AU - Williams, L.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - At the University of Nebraska Medical Center (UNMC), a protocol was instituted in July 1985 for the use of OKT3 on a compassionate basis for patients who failed treatment of acute rejection with both steroids and Atgam. (ATG). This paper summarizes the results of our conventional immunosuppression with cyclosporine (Cs) and steroids, conventional therapy for acute rejection including steroids and ATG, and compassionate use of OKT3. We conclude that reserving OKT3 for use as the final-line therapy, after SR and Atgam have failed, yields results inferior to those obtained when OKT3 is used to treat steroid-resistant rejections. Our experience has shown, however, that most rejection episodes after OLT are readily reversed by using steroid therapy as outlined. From the data presented, OKT3 is at least as effective as Atgam in treating steroid-resistant rejections. In addition, OKT3 has the added advantage of being readily available and does not appear to be associated with a higher incidence of complications than does Atgam therapy.

AB - At the University of Nebraska Medical Center (UNMC), a protocol was instituted in July 1985 for the use of OKT3 on a compassionate basis for patients who failed treatment of acute rejection with both steroids and Atgam. (ATG). This paper summarizes the results of our conventional immunosuppression with cyclosporine (Cs) and steroids, conventional therapy for acute rejection including steroids and ATG, and compassionate use of OKT3. We conclude that reserving OKT3 for use as the final-line therapy, after SR and Atgam have failed, yields results inferior to those obtained when OKT3 is used to treat steroid-resistant rejections. Our experience has shown, however, that most rejection episodes after OLT are readily reversed by using steroid therapy as outlined. From the data presented, OKT3 is at least as effective as Atgam in treating steroid-resistant rejections. In addition, OKT3 has the added advantage of being readily available and does not appear to be associated with a higher incidence of complications than does Atgam therapy.

UR - http://www.scopus.com/inward/record.url?scp=0023900665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023900665&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 254

EP - 259

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 1 SUPPL. 1

ER -